



Središnja medicinska knjižnica

This is the peer reviewed version of the following article:

Lucijanić M., Kušec R. (2019) *Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome?* British Journal of Haematology, 186 (4). pp. 640-641. ISSN 0007-1048

which has been published in final form at <http://doi.org/10.1111/bjh.15943>. This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

[http://onlinelibrary.wiley.com/journal/10.1111/\(ISSN\)1365-2141](http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2141)

<http://doi.org/10.1111/bjh.15943>

<http://medlib.mef.hr/3692>

University of Zagreb School of Medicine Repository

<http://medlib.mef.hr/>

Title: Could haemochromatosis (*HFE*) gene mutations affect response to iron chelation in myelodysplastic syndrome?

Authors: Marko Lucijanic¹, Rajko Kusec^{1,2}

Affiliations:

¹Haematology Department, University Hospital Dubrava, Zagreb, Croatia

²School of Medicine, University of Zagreb, Zagreb, Croatia

Corresponding author: Marko Lucijanic, MD PhD, Haematology Department, University hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb. Tel: +38512902444. Email: markolucijanic@yahoo.com

Competing interests: both authors state they have no competing interests

Funding: none

Acknowledgements: ML and RK drafted and critically revised the letter

Dear Editor,

We have read the paper by Fabiani et al. (Fabiani, *et al* 2018) investigating potential molecular mechanisms behind haematological improvement (HI) during iron chelation therapy (ICT) in patients with lower risk myelodysplastic syndrome (MDS) with great interest. Authors reported that neither patients' characteristics (including baseline and follow-up ferritin concentrations), nor mutations in any of the specific genes frequently mutated in myeloid malignancies showed significant associations with the occurrence of HI during ICT. We would like to point out that haemochromatosis (*HFE*) gene mutations which are affecting significant proportion of MDS patients and increase the risk of iron accumulation in this context (De Souza, *et al* 2015, Lucijanic, *et al* 2016) were not assessed by the authors in the current study.

Heterozygosity for *HFE* gene mutations is an equally common feature in both MDS patients and healthy population. Mutations show variable geographic distribution and affect up to one third of MDS patients when considering two most frequent mutations (C282Y, H63D) (Lucijanic, *et al* 2016). Although considered not to be directly implicated in the pathobiology of MDS and not to significantly affect iron accumulation in the general population (Burt, *et al* 1998, Jackson, *et al* 2001, Rossi, *et al* 2001), heterozygosity for *HFE* gene mutations was shown to intensify iron overload in transfusion-dependent (De Souza, *et al* 2015) and accelerate iron accumulation in transfusion-independent MDS patients (Lucijanic, *et al* 2016). Most interestingly, *HFE* mutated patients seem to experience significantly shorter overall and leukaemia free survival (Lucijanic, *et al* 2016). Therefore, question emerges whether *HFE* mutated MDS patients might require lower thresholds to start chelation therapy and/or more intensive chelation to achieve response, but these issues have not been sufficiently investigated at the moment.

We congratulate the authors of the current work (Fabiani, *et al* 2018) on the valuable insight into the biology of MDS. However, mechanisms behind amelioration of iron overload and improvement in haematopoietic function still remain elusive. Since *HFE* gene mutations seem to significantly modulate iron metabolism in MDS, it would be very interesting to see whether they affect the odds of acquiring HI during ICT and how do they distribute among investigated somatic mutations. We hope that authors could provide such analysis.

References:

- Burt, M.J., George, P.M., Upton, J.D., Collett, J.A., Frampton, C.M., Chapman, T.M., Walmsley, T.A. & Chapman, B.A. (1998) The significance of haemochromatosis gene mutations in the general population: implications for screening. *Gut*, **43**, 830-836.
- De Souza, G.F., Ribeiro, H.L., Jr., De Sousa, J.C., Heredia, F.F., De Freitas, R.M., Martins, M.R., Goncalves, R.P., Pinheiro, R.F. & Magalhaes, S.M. (2015) HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study. *BMJ Open*, **5**, e006048.
- Fabiani, E., Calabrese, C., Niscola, P., Balleari, E., Molteni, A., Finelli, C., Falconi, G., Fenu, S., Fianchi, L., Criscuolo, M., Salvi, F., Lavorgna, S., Buccisano, F., Maurillo, L., Lo Coco, F., Cilloni, D. & Voso, M.T. (2018) Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS). *Br J Haematol*.
- Jackson, H.A., Carter, K., Darke, C., Guttridge, M.G., Ravine, D., Hutton, R.D., Napier, J.A. & Worwood, M. (2001) HFE mutations, iron deficiency and overload in 10,500 blood donors. *Br J Haematol*, **114**, 474-484.

Lucijanic, M., Pejsa, V., Mitrovic, Z., Stoos-Veic, T., Livun, A., Jaksic, O., Vasilj, T., Pirsic, M., Haris, V., Prka, Z. & Kusec, R. (2016) Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome. *Hematology*, **21**, 170-174.

Rossi, E., Bulsara, M.K., Olynyk, J.K., Cullen, D.J., Summerville, L. & Powell, L.W. (2001) Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. *Clin Chem*, **47**, 202-208.